search
Crispr
Trends
- 1Single CRISPR Treatment Halves Bad Cholesterol for a Year▼One CRISPR treatment cut “bad” cholesterol in half for a full year
A one-time CRISPR gene-editing treatment reportedly cut LDL, or "bad," cholesterol roughly in half, with effects lasting a full year. The finding suggests gene editing could one day offer a durable alternative to daily statins for people at risk of heart disease. Coverage is drawing attention to the potential of permanent, single-dose therapies for one of the world's leading causes of death, though longer and larger trials will be needed before wide use.
- 2Engineered mini CRISPR enzyme gets 60-fold power boost▼Engineered mini CRISPR enzyme gets a 60-fold power boost for gene editing
Researchers report engineering a compact CRISPR enzyme with a 60-fold increase in gene-editing power. The mini enzyme, if validated, could make gene therapies more efficient with smaller delivery vehicles, a key limitation in current CRISPR treatments. Coverage in the biology community highlights the size-and-strength tradeoff as a notable advance for therapeutic and research applications.
- 3Epigenetic Editing Edges Closer to Clinical Use▼Epigenetic Editing Steps Closer to the Clinic as Bioengineering Tools Mature
Reports say epigenetic editing — altering gene activity without changing DNA sequence — is moving closer to clinical application as the bioengineering tools behind it mature. Unlike CRISPR-style gene cutting, epigenetic approaches aim to switch genes on or off reversibly, and researchers see growing potential for treating disease with fewer permanent risks. The field is watching which tools and trials will translate first.
- 4What's The Latest On CRISPR Gene Editing Technology?▼What’s The Latest On CRISPR Gene Editing Technology?
Forbes is asking what the latest developments are in CRISPR gene editing technology. The field continues to move quickly, with gene-editing therapies and research advancing across medicine and biotechnology. Readers are following the topic as new treatments and regulatory decisions keep gene editing in the public eye.
- 5CRISPR-Edited Plants Need a Sustainable Innovation System▼CRISPR Beyond the Lab: Why Genome-Edited Plants Need a Sustainable Innovation System
Commentary argues that CRISPR genome-edited plants must move beyond laboratory success into a broader sustainable innovation system covering regulation, farming practice and commercialisation. The piece stresses that editing crops is only one step; lasting impact depends on infrastructure, policy and responsible deployment in agriculture.
- 6Study maps rational selection of adenine base editors for human genome editing●Rational selection of SpCas9 and variant-derived adenine base editors for human genome editing
A Nature publication describes a rational framework for choosing between SpCas9 and variant-derived adenine base editors when editing the human genome. The work aims to help researchers match editor choice to specific target sites and desired edits, improving precision in gene-editing applications. The paper is being circulated among readers following advances in CRISPR-based genome editing tools.
- 7Anthropic Says Its AI Discovered a CRISPR-Like Enzyme System▼Anthropic Says Its A.I. Discovered a New Enzyme System That Resembles the Revolutionary Gene-Editing Tool CRISPR
Anthropic announced that its artificial intelligence identified a previously unknown enzyme system resembling CRISPR, the gene-editing tool that transformed biology. The claim suggests AI can uncover novel biological mechanisms, not just analyze existing data. Details on the discovery, its validation, and practical uses remain limited so far, and scientists will be watching for independent confirmation.
- 8Anthropic Claims Discovery of Crispr-Like Gene-Editing System●Anthropic Says It Discovered a Crispr-Like System. Now What? https:// fed.brid.gy/r/https://www.wire d.com/story/anthrop
Wired reports that AI company Anthropic says it has discovered a biological system resembling Crispr, the landmark gene-editing tool. The claim has drawn attention because it suggests an AI firm moving beyond software into biology research, raising questions about what the finding actually is, how it was verified, and what practical applications might follow. Details remain limited as observers wait for scientific scrutiny of the announcement.